CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

(2018) Joseph M. Connors et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial

(2017) Marc P.E. André et al.   JOURNAL OF CLINICAL ONCOLOGY

Limited-Stage Hodgkin Lymphoma: Clarifying Uncertainty

(2017) Ralph M. Meyer   JOURNAL OF CLINICAL ONCOLOGY

Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP escalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group

(2017) Peter Borchmann et al.   LANCET ONCOLOGY

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816

(2016) Oliver W. Press et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma

(2016) Peter Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Radiation Therapy for Hodgkin Lymphoma—Can It Be Administered More Safely if Necessary?

(2016) David J. Straus et al.   JAMA Oncology

Late Morbidity and Mortality in Patients with Hodgkin's Lymphoma Treated During Adulthood

(2015) M. J. Matasar et al.   JNCI-Journal of the National Cancer Institute

Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma

(2015) John Radford et al.   NEW ENGLAND JOURNAL OF MEDICINE

Late Morbidity and Mortality in Patients with Hodgkin's Lymphoma Treated During Adulthood

(2015) M. J. Matasar et al.   JNCI-Journal of the National Cancer Institute

ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial†

(2014) N. Mounier et al.   ANNALS OF ONCOLOGY

Role of FDG-PET in the Implementation of Involved-Node Radiation Therapy for Hodgkin Lymphoma Patients

(2014) Théodore Girinsky et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

In Vivo Treatment Sensitivity Testing With Positron Emission Tomography/Computed Tomography After One Cycle of Chemotherapy for Hodgkin Lymphoma

(2014) Martin Hutchings et al.   JOURNAL OF CLINICAL ONCOLOGY

Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial

(2014) John M.M. Raemaekers et al.   JOURNAL OF CLINICAL ONCOLOGY

On Sample Size Calculation for Comparing Survival Curves Under General Hypothesis Testing

(2012) Sin-Ho Jung et al.   Journal of Biopharmaceutical Statistics

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

(2011) D. J. Straus et al.   BLOOD

ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma

(2011) Ralph M. Meyer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial

(2010) Hans Theodor Eich et al.   JOURNAL OF CLINICAL ONCOLOGY

Report on the First International Workshop on interim-PET scan in lymphoma

(2009) Michel Meignan et al.   LEUKEMIA & LYMPHOMA